<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1857">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441684</url>
  </required_header>
  <id_info>
    <org_study_id>7782</org_study_id>
    <nct_id>NCT04441684</nct_id>
  </id_info>
  <brief_title>Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)</brief_title>
  <acronym>SeroCoV-HUS</acronym>
  <official_title>Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with
      no specific therapeutic options.

      Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden
      increase of patients with COVID-19 resulted from a SARS-CoV-2 superspreading event (religious
      meeting). Infected individuals went to regional hospitals, and this led to a cluster of
      infected healthcare workers at the Strasbourg University Hospitals from the first week of
      March. To date, several hundred Strasbourg hospital workers have presented a SARS-CoV-2
      infection confirmed by the RT-PCR test from a nasopharyngeal sample. Most of them developed a
      mild form of COVID-19.

      It is important to understand how far the infection has spread in the hospital staff, and to
      which extent the individuals who have been infected develop antibodies against SARS-CoV-2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of specific SARS-CoV2 antibodies in the serum in the 3 groups of subjects studied, at the inclusion visit (D0).</measure>
    <time_frame>inclusion visit (Day 0).</time_frame>
    <description>Presence of specific SARS-CoV2 antibodies in the serum in the 3 groups of subjects studied, at the inclusion visit (D0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection and titration of neutralizing antibodies anti-SARS-CoV-2</measure>
    <time_frame>At Day 0 and each follow-up visits i.e. at Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) and Month 12 (Day 0+12 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kinetics of antibodies and their persistence over a period of 1 year</measure>
    <time_frame>At Day 0 and each follow-up visits i.e. at Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) and Month 12 (Day 0+12 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of asymptomatic subjects in the PCR - and -PCR groups</measure>
    <time_frame>At Day 0 and each follow-up visits i.e. at Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) and Month 12 (Day 0+12 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of people with positive Sars-CoV-2 serology</measure>
    <time_frame>At Day 0 and each follow-up visits i.e. at Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) and Month 12 (Day 0+12 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire (Type of health care personnel, Contact history, medical operation and respect of hygiene standards)</measure>
    <time_frame>At Day 0 and each follow-up visits i.e. at Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) and Month 12 (Day 0+12 months).</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of the T cell response by the ELISPOT technique</measure>
    <time_frame>At one of the follow up visit : Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) or Month 12 (Day 0+12 months).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>B cell repertoire sequencing</measure>
    <time_frame>At one of the follow up visit : Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) or Month 12 (Day 0+12 months).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sequencing of cellular SARS-CoV2 receptors</measure>
    <time_frame>At one of the follow up visit : Month 3 (Day 0+3 months), Month 6 (Day 0+6 months) or Month 12 (Day 0+12 months).</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>SARS-CoV-2 Serological Status</condition>
  <condition>SARS-CoV-2 Seroprevalence</condition>
  <arm_group>
    <arm_group_label>PCR+ group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group includes any symptomatic person with a positive COVID result, with a RT-PCR test carried out at least 10 days before inclusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCR- group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group includes any symptomatic person with a negative RT-PCR COVID 19 test carried out at least 10 days before inclusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No PCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group includes any person, for which no COVID 19 RT- PCR testing was performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample for serological test</intervention_name>
    <description>Serology tests:
By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland
ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA
Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.</description>
    <arm_group_label>No PCR</arm_group_label>
    <arm_group_label>PCR+ group</arm_group_label>
    <arm_group_label>PCR- group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any person, male or female, over 18 years of age at the time of signing the consent

          -  Any person affiliated to a social health insurance scheme

          -  Any person able to understand the objectives and risks related to research and to give
             an informed, dated and signed consent

          -  Any person who is part of HUS staff and working at HUS at the time of the pandemic,
             including residents affiliated with HUS and assigned to general hospitals in the
             region

          -  Any symptomatic person with a positive COVID result (PCR + group) or negative (PCR-
             group) with a RT-PCR test carried out at least 10 days before inclusion, or any
             person, for which no COVID PCR was performed (group &quot; No PCR&quot;)

        Exclusion Criteria:

          -  Person in exclusion period (determined by a previous or ongoing study),

          -  Inability to give clear information (person in an emergency, difficulty understanding
             the subject, etc.)

          -  Person under safeguard of justice

          -  Person under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samira FAFI-KREMER, MD PhD</last_name>
    <phone>+33 3 69 55 14 38</phone>
    <email>samira.fafi-kremer@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel Hôpital Civil et Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine MUTTER, MD</last_name>
      <email>catherine.mutter@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jérôme DE SEZE, MD PhD</last_name>
      <email>jerome.deseze@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Samira FAFI-KREMER, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David REY, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria PARTISANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria GONZALEZ, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine MUTTER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie MIELCAREK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérôme DE SEZE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas COLLONGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie PHILIPPI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Livia LANOTTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Céline FLEURY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandra NADAJ-PAKLEZA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Baptiste CHANSON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent KREMER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Aude SPITZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves HANSMANN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas LEFEBVRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Humoral response</keyword>
  <keyword>T-cell response</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

